Moreover, many other elements of care that are tumour-group-specific are absent from the QIs extracted; for example, BRCA1 and BRCA2 genetic testing to guide treatment decisions in ovarian cancer as per the Society of Gynaecologic Oncology [43]. This evidence concerns the gene BRCA1 and ovarian carcinoma.